{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T06:15:29Z","timestamp":1783318529694,"version":"3.54.6"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Chimeric antigen receptor T-cell (CAR-T) therapies have shown potential in clinical trials for glioblastoma, yet treatment responses vary due to heterogeneous antigen expression and post-treatment immune escape. NKG2D\u2212based CAR-T cells have exhibited a favorable safety profile in patients with hematologic malignancies and demonstrated potent antitumor activity in xenograft models, including those of glioblastoma. Nevertheless, glioma cells could evade immune recognition by downregulating or proteolytically shedding NKG2D ligands. To enhance the efficacy of NKG2D CAR-T therapy, we investigated its combination with preclinical agents capable of penetrating the blood-brain barrier that could upregulate NKG2D ligands on glioma cells. Our study revealed that resveratrol (RSV), a bioactive polyphenol, significantly increased the surface expression of NKG2D ligands on glioblastoma cells. RSV pretreatment sensitized these cells to NKG2D CAR-T-mediated killing\n                    <jats:italic>in vitro<\/jats:italic>\n                    . Additionally, the combination of RSV with NKG2D CAR-T cells demonstrated potent antitumor activity\n                    <jats:italic>in vivo.<\/jats:italic>\n                    Mechanistically, RSV potentially induced NKG2D ligand expression via activation of the p53 signaling pathway. These preclinical findings identify RSV as a promising pharmacological adjuvant that enhances NKG2D CAR-T efficacy in glioblastoma, supporting further translational and clinical evaluation of this combinatory approach.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2026.1831927","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T05:38:56Z","timestamp":1783316336000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Combinatorial therapy with resveratrol sensitizes glioblastoma to NKG2D CAR-T cells"],"prefix":"10.3389","volume":"17","author":[{"given":"Wei","family":"Liang","sequence":"first","affiliation":[{"name":"Guangdong Immune Cell Therapy Engineering and Technology Research Center, Center for Protein and Cell-based Drugs, Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences","place":["Shenzhen, China"]},{"name":"University of Chinese Academy of Sciences","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yexiao","family":"Tang","sequence":"additional","affiliation":[{"name":"Cancer Center, Shenzhen University of Advanced Technology General Hospital","place":["Shenzhen, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Auwal","family":"Saliu","sequence":"additional","affiliation":[{"name":"Guangdong Immune Cell Therapy Engineering and Technology Research Center, Center for Protein and Cell-based Drugs, Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences","place":["Shenzhen, China"]},{"name":"University of Chinese Academy of Sciences","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansur Dabai","family":"Salisu","sequence":"additional","affiliation":[{"name":"Guangdong Immune Cell Therapy Engineering and Technology Research Center, Center for Protein and Cell-based Drugs, Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences","place":["Shenzhen, China"]},{"name":"University of Chinese Academy of Sciences","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuimei","family":"Chen","sequence":"additional","affiliation":[{"name":"School of Public Health, Xiangnan University","place":["Chenzhou, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiming","family":"Xu","sequence":"additional","affiliation":[{"name":"Cancer Center, Shenzhen University of Advanced Technology General Hospital","place":["Shenzhen, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Xu","sequence":"additional","affiliation":[{"name":"Cancer Center, Shenzhen University of Advanced Technology General Hospital","place":["Shenzhen, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maoxuan","family":"Liu","sequence":"additional","affiliation":[{"name":"Guangdong Immune Cell Therapy Engineering and Technology Research Center, Center for Protein and Cell-based Drugs, Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences","place":["Shenzhen, China"]},{"name":"University of Chinese Academy of Sciences","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochun","family":"Wan","sequence":"additional","affiliation":[{"name":"Guangdong Immune Cell Therapy Engineering and Technology Research Center, Center for Protein and Cell-based Drugs, Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences","place":["Shenzhen, China"]},{"name":"University of Chinese Academy of Sciences","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70265-6","article-title":"Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial","volume":"13","author":"Malmstr\u00f6m","year":"2012","journal-title":"Lancet Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-024-01226-x","article-title":"Immunotherapy for glioblastoma: current state, challenges, and future perspectives","volume":"21","author":"Liu","year":"2024","journal-title":"Cell Mol Immunol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41568-019-0224-7","article-title":"Brain immunology and immunotherapy in brain tumours","volume":"20","author":"Sampson","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0792-9","article-title":"Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial","volume":"565","author":"Keskin","year":"2019","journal-title":"Nature"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noz040","article-title":"Phase I\/II trial testing safety and immunogenicity of the multipeptide IMA950\/poly-ICLC vaccine in newly diagnosed adult Malignant astrocytoma patients","volume":"21","author":"Migliorini","year":"2019","journal-title":"Neuro-Oncology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0337-7","article-title":"Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma","volume":"25","author":"Cloughesy","year":"2019","journal-title":"Nat Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0339-5","article-title":"Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma","volume":"25","author":"Schalper","year":"2019","journal-title":"Nat Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2017.1363139","article-title":"Trial Watch: Adoptively transferred cells for anticancer immunotherapy","volume":"6","author":"Fournier","year":"2017","journal-title":"Oncoimmunology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.03.004","article-title":"CAR T cell therapy for glioblastoma: a review of the first decade of clinical trials","volume":"33","author":"Begley","year":"2025","journal-title":"Mol Ther: J Am Soc Gene Ther"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-019-0192-1","article-title":"CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity","volume":"37","author":"Choi","year":"2019","journal-title":"Nat Biotechnol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1255611","article-title":"Immunotherapy: a promising approach for glioma treatment","volume":"14","author":"Yasinjan","year":"2023","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/nri1199","article-title":"Roles of the NKG2D immunoreceptor and its ligands","volume":"3","author":"Raulet","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00097","article-title":"NKG2D ligands in tumor immunity: two sides of a coin","volume":"6","author":"Zhang","year":"2015","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/nri2144","article-title":"Promiscuity and the single receptor: NKG2D","volume":"7","author":"Eagle","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1301071","article-title":"Immunobiology and conflicting roles of the human NKG2D lymphocyte receptor and its ligands in cancer","volume":"191","author":"El-Gazzar","year":"2013","journal-title":"J Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-18-0307","article-title":"Phase I trial of autologous CAR T cells targeting NKG2D ligands in patients with AML\/MDS and multiple myeloma","volume":"7","author":"Baumeister","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s40425-019-0642-9","article-title":"T cells expressing NKG2D chimeric antigen receptors efficiently eliminate glioblastoma and cancer stem cells","volume":"7","author":"Yang","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.4161\/onci.28497","article-title":"Secretory pathways generating immunosuppressive NKG2D ligands: new targets for therapeutic intervention","volume":"3","author":"Baraga\u00f1o Raneros","year":"2014","journal-title":"Oncoimmunology"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awl205","article-title":"TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on Malignant glioma cells","volume":"129","author":"Eisele","year":"2006","journal-title":"Brain: A J Neurol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2019.04.007","article-title":"Epigenetic inhibition puts target antigen in the crosshairs of CAR T cells","volume":"27","author":"Steffin","year":"2019","journal-title":"Mol Ther: J Am Soc Gene Ther"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2019.10034","article-title":"Resveratrol induces p53 in colorectal cancer through SET7\/9","volume":"17","author":"Liu","year":"2019","journal-title":"Oncol Lett"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25063370","article-title":"Resveratrol as a promising nutraceutical: implications in gut microbiota modulation, inflammatory disorders, and colorectal cancer","volume":"25","author":"Prakash","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/fsn3.3817","article-title":"Resveratrol prevents age-related heart impairment through inhibiting the Notch\/NF-\u03baB pathway","volume":"12","author":"Wang","year":"2024","journal-title":"Food Sci Nutr"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-21-517","article-title":"Resveratrol affects the migration and apoptosis of monocytes by blocking HMGB1\/NF-\u03baB pathway","volume":"10","author":"Zhang","year":"2021","journal-title":"Trans Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jnutbio.2022.109083","article-title":"Synergistic anti-inflammatory effects and mechanisms of the combination of resveratrol and curcumin in human vascular endothelial cells and rodent aorta","volume":"108","author":"Zhang","year":"2022","journal-title":"J Nutr Biochem"},{"key":"B26","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1186\/s12951-022-01554-y","article-title":"Curcumin- and resveratrol-co-loaded nanoparticles in synergistic treatment of hepatocellular carcinoma","volume":"20","author":"Zheng","year":"2022","journal-title":"J Nanobiotechnol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110116","article-title":"Resveratrol slows the tumourigenesis of pancreatic cancer by inhibiting NF\u03baB activation","volume":"127","author":"Qian","year":"2020","journal-title":"Biomed Pharmacother = Biomed Pharmacother"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242316597","article-title":"Therapeutic potential of resveratrol for glioma: a systematic review and meta-analysis of animal model studies","volume":"24","author":"Lu\u00eds","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1519777","article-title":"Sodium valproate enhances efficacy of NKG2D CAR-T cells against glioblastoma","volume":"15","author":"Liu","year":"2024","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1007\/s00018-025-05746-1","article-title":"Dual phosphorylation of glycogen synthase kinase 3\u03b2 differentially integrates metabolic programs to determine T cell immunity across vertebrates","volume":"82","author":"Liang","year":"2025","journal-title":"Cell Mol Life Sci: CMLS"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noy032","article-title":"CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges","volume":"20","author":"Bagley","year":"2018","journal-title":"Neuro-Oncology"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noae203","article-title":"Chimeric antigen receptor T-cell therapy in patients with Malignant glioma-from neuroimmunology to clinical trial design considerations","volume":"27","author":"Gallus","year":"2025","journal-title":"Neuro-Oncology"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-19-0026","article-title":"Eradication of hepatocellular carcinoma by NKG2D-based CAR-T cells","volume":"7","author":"Sun","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/j.0105-2896.2010.00893.x","article-title":"Effect of NKG2D ligand expression on host immune responses","volume":"235","author":"Champsaur","year":"2010","journal-title":"Immunol Rev"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.19445","article-title":"Resveratrol promotes MICA\/B expression and natural killer cell lysis of breast cancer cells by suppressing c-Myc\/miR-17 pathway","volume":"8","author":"Pan","year":"2017","journal-title":"Oncotarget"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12141","article-title":"Ataxia-telangiectasia mutated kinase-mediated upregulation of NKG2D ligands on leukemia cells by resveratrol results in enhanced natural killer cell susceptibility","volume":"104","author":"Luis Espinoza","year":"2013","journal-title":"Cancer Sci"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.19601","article-title":"Resveratrol sensitized leukemia stem cell-like KG-1a cells to cytokine-induced killer cells-mediated cytolysis through NKG2D ligands and TRAIL receptors","volume":"13","author":"Hu","year":"2012","journal-title":"Cancer Biol Ther"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20061283","article-title":"Killing mechanisms of chimeric antigen receptor (CAR) T cells","volume":"20","author":"Benmebarek","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B39","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jemermed.2020.04.021","article-title":"Management of chimeric antigen receptor (CAR) T-cell toxicities: a review and guideline for emergency providers","volume":"59","author":"Gupta","year":"2020","journal-title":"J Emergency Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.2287","article-title":"MicroRNA-mediated down-regulation of NKG2D ligands contributes to glioma immune escape","volume":"5","author":"Zhu","year":"2014","journal-title":"Oncotarget"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-013-1231-0","article-title":"The narrow-spectrum HDAC inhibitor entinostat enhances NKG2D expression without NK cell toxicity, leading to enhanced recognition of cancer cells","volume":"32","author":"Codo","year":"2015","journal-title":"Pharm Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-08-173914","article-title":"ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype","volume":"113","author":"Soriani","year":"2009","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0901797","article-title":"Heat shock protein-90 inhibitors increase MHC class I-related chain A and B ligand expression on multiple myeloma cells and their ability to trigger NK cell degranulation","volume":"183","author":"Fionda","year":"2009","journal-title":"J Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1515605","article-title":"Resveratrol contributes to NK cell-mediated breast cancer cytotoxicity by upregulating ULBP2 through miR-17-5p downmodulation and activation of MINK1\/JNK\/c-Jun signaling","volume":"16","author":"Ding","year":"2025","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1831927\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T05:38:57Z","timestamp":1783316337000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1831927\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":44,"alternative-id":["10.3389\/fimmu.2026.1831927"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1831927","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]},"article-number":"1831927"}}